Pfizer (PFE) Stock Rallies 4% Thanks to Merck (MRK) and Moderna (MRNA)’s Cancer Trial Update
Pfizer stock was up 3.74% thanks to a clinical trial update from Merck and Moderna that showed the potential of an MRNA vaccine as a cancer treatme...
Moderna Inc. (MRNA)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Theleme Partners Patrick Degorce | 8,057,571 | $564,271,697 | +1% | 33.52% |
| 2. | 3,026,200 | $211,924,786 | -16% | 0.02% | |
| 3. | 2,911,800 | $203,913,354 | -3% | 0.02% | |
| 4. | BAMCO Inc. Ron Baron | 1,989,386 | $139,316,702 | 0.21% | |
| 5. | 1,943,700 | $136,117,311 | +131% | 0.51% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $31.53 | 57,493 | $1,812,754.29 | 9,210,686 | 2025-03-03 | Filing | |
| $31.04 | 102,821 | $3,191,563.84 | 9,153,193 | 2025-03-03 | Filing | |
| $31.76 | 31,620 | $1,004,251.20 | 312,027 | 2025-03-03 | Filing | |
| $19.00 | 52,631 | $999,989.00 | 420,407 | 2020-02-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $58.79 | 187,044 | $10,996,316.76 | 6,187,791 | 2026-08-05 | Filing | |
| $58.12 | 39,891 | $2,318,464.92 | 6,374,835 | 2026-08-05 | Filing | |
| $56.96 | 124,838 | $7,110,772.48 | 6,414,726 | 2026-08-05 | Filing | |
| $56.21 | 147,473 | $8,289,457.33 | 6,539,564 | 2026-08-05 | Filing | |
| $67.60 | 53,336 | $3,605,513.60 | 1,483,848 | 2026-07-15 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 51,859,891 | $3,631,748,191 | 0.16% | |
| 2. | 30,599,409 | $2,142,876,625 | 0.03% | |
| 3. | 23,208,792 | $1,625,311,704 | 0.03% | |
| 4. | 22,276,996 | $1,560,053,964 | 0.18% | |
| 5. | 18,206,778 | $1,275,020,663 | 1.16% |
News See All
Why Moderna Stock Is Rallying Today — and What Wall Street Expects Next
Moderna (NASDAQ:MRNA) stock is jumping over 100% on Wednesday after the biotech delivered the kind of cancer-treatment result investors have waited...
Moderna Stock Soars 100% after “Landmark” Phase 3 Cancer Trial Win in Melanoma
Moderna, Inc. ($MRNA), the biotech company best known for its mRNA vaccines, surged about 100% in pre-market trading Wednesday after its personaliz...
Why Is Moderna Stock (MRNA) Surging Over 100% in Pre-Market Today, August 19?
Merck ($MRK) and Moderna ($MRNA) stocks are surging in pre-market trading Wednesday after the companies announced positive Phase 3 results for thei...
Could Arbutus Biopharma Corporation (ABUS) Turn its Moderna, Inc. (MRNA) Settlement Into a Lasting Biotech Advantage?
A landmark legal settlement in the biotech sector recently reshaped the financial trajectories of two key mRNA technology players: Arbutus Biopharma Corporation (NASDAQ:ABUS) and Moderna, Inc.
Moderna Stock Slips Despite FDA Approval for New Flu Shot mFlusiva
Moderna stock ($MRNA) fell 1.5% to $55.39 on Thursday despite getting big news from health regulators. The Food and Drug Administration approved Mo...
Moderna Stock (MRNA) Jumps on U.S. Approval for New Flu Shot Type — Why This Matters
Shares in Moderna ($MRNA) rose about 4% early Thursday after the pharma and biotech firm received the go-ahead from the U.S. health watchdog to sel...
Moderna Wins a Post-COVID Earnings Beat as Analyst Eyes ‘Clinically Meaningful’ Trial Results
Moderna’s ($MRNA) latest earnings were better-than-expected. Jefferies ($JEF) analyst Andrew Tsai explained that while quarterly earnings beat expe...
Polymarket Odds: Will MRNA, XOM, CVX Beat Earnings Tomorrow?
On Friday, July 31, Moderna ($MRNA), Exxon Mobil ($XOM), and Chevron ($CVX) will release their earnings. All three companies will report before the...
Moderna Stock Has Doubled in 2026, But Wall Street Still Isn't Convinced
The year 2026 has turned into a pivotal year for the biotech capital markets.
Hedge Fund Resource Center